"We are committed to creating the future of oncology by developing innovative therapies that address unmet medical needs"
Ability Pharmaceuticals
ABOUT
"We are committed to creating the future of oncology by developing innovative therapies that address unmet medical needs"
Ability Pharmaceuticals
LATEST NEWS
News
Ability Pharmaceuticals Announces the Approval in China of a Clinical Study in Pancreatic Cancer with ABTL0812 + infoNews
Ability Pharmaceuticals is attending the BIOMED EVENT® by INVEST SECURITIES and the Cholangiocarcinoma Foundation Annual Conference + infoNews
AbilityPharma ha superado el millón de euros en la ronda de crowdfunding que abrió el pasado mes de septiembre + infoNews
Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Biliary Tract Cancer + infoNews
Ability Pharmaceuticals anuncia la inclusión del primer paciente en el estudio clínico de la fase 2 de ABTL0812 en Francia + infoNews
At AbilityPharma we are very pleased to announce the start of a crowdfunding campaign through de Capital Cell + infoNews
AbilityPharma Announces FDA Approval of Phase 1/2 Trial of ABTL0812 for Patients with Advanced Metastatic Pancreatic Cancer + infoNews
AbilityPharma Announces FDA Approval of IND for Phase 2 Trial of ABTL0812 in Patients with Endometrial Cancer or Squamous Non-Small Cell Lung Cancer + infoNews
Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France + info
Carretera antiga Amer nº 10
17007 • Girona
T. 972 909 999
E. info@neorgsite.com
http://www.neorgsite.com